VALD Secures Significant Growth Equity Investment from FTV Capital
VALD, a global health technology company specializing in musculoskeletal (MSK) health, has secured a significant growth equity investment from FTV Capital. This investment will enable VALD to expand geographically, enhance product capabilities, and cement its position as a global technology pioneer in MSK health.
VALD's comprehensive suite of MSK technologies helps health professionals enhance diagnostic capabilities and capture real-time data, driving better outcomes. The company has shown market-leading growth, with revenue more than tripling since 2021 and staff in over 30 countries. VALD serves global blue-chip customers, including 75% of major league sports franchises, 90% of Power 5 NCAA colleges, and numerous health systems and clinics.
The investment will allow VALD to grow its global team, launch new product offerings, and continue utilizing AI to create unique applications for its proprietary dataset of tens of millions of MSK health records.
VALD, un'azienda globale nel settore della tecnologia sanitaria specializzata nella salute muscoloscheletrica (MSK), ha ottenuto un'importante investimento di crescita azionaria da FTV Capital. Questo investimento permetterà a VALD di espandersi geograficamente, migliorare le capacità dei prodotti e consolidare la sua posizione come pioniere globale della tecnologia nella salute MSK.
La suite completa di tecnologie MSK di VALD aiuta i professionisti della salute a migliorare le capacità diagnostiche e a catturare dati in tempo reale, generando migliori risultati. L'azienda ha mostrato una crescita leader di mercato, con entrate più che triplicate dal 2021 e personale in oltre 30 paesi. VALD serve clienti globali di alto livello, inclusa il 75% delle principali franchise sportive, il 90% delle università Power 5 NCAA e numerosi sistemi sanitari e cliniche.
L'investimento consentirà a VALD di crescere il suo team globale, lanciare nuove offerte di prodotti e continuare a utilizzare l'IA per creare applicazioni uniche per il suo dataset proprietario di decine di milioni di registrazioni sanitarie MSK.
VALD, una empresa global de tecnología en salud especializada en salud musculoesquelética (MSK), ha asegurado una importante inversión de capital de crecimiento por parte de FTV Capital. Esta inversión permitirá a VALD expandirse geográficamente, mejorar las capacidades del producto y afianzar su posición como pionero tecnológico global en salud MSK.
El conjunto integral de tecnologías MSK de VALD ayuda a los profesionales de la salud a mejorar las capacidades de diagnóstico y a capturar datos en tiempo real, obteniendo mejores resultados. La empresa ha mostrado un crecimiento líder en el mercado, con ingresos más que triplicados desde 2021 y personal en más de 30 países. VALD atiende a clientes globales de primer nivel, incluyendo el 75% de las franquicias deportivas de las grandes ligas, el 90% de las universidades Power 5 de la NCAA, y numerosos sistemas de salud y clínicas.
La inversión permitirá a VALD hacer crecer su equipo global, lanzar nuevas ofertas de productos y continuar utilizando IA para crear aplicaciones únicas para su conjunto de datos propietario de decenas de millones de registros de salud MSK.
VALD는 근골격계(MSK) 건강을 전문으로 하는 글로벌 헬스 테크놀로지 회사로, FTV Capital로부터 상당한 성장 자본 투자를 확보했습니다. 이 투자는 VALD가 지리적으로 확장, 제품 기능을 향상시키고, MSK 건강 분야에서 글로벌 기술 선도자로서의 입지를 확고히 하는 데 도움이 될 것입니다.
VALD의 포괄적인 MSK 기술 모음은 건강 전문가들이 진단 능력을 향상시키고 실시간 데이터를 수집하는 데 도움을 주어 더 나은 결과를 도출하도록 합니다. 회사는 2021년 이후 수입이 세 배 이상 증가하고, 30개국 이상에서 직원이 근무하는 등 시장 선도적인 성장을 보여주었습니다. VALD는 주요 리그 스포츠 프랜차이즈의 75%, Power 5 NCAA 대학의 90% 및 수많은 의료 시스템과 클리닉을 포함한 글로벌 블루칩 고객에게 서비스를 제공합니다.
이번 투자는 VALD가 글로벌 팀을 성장시키고, 신제품을 출시하며, 자체 건강 기록 데이터 세트의 수천만 개의 MSK 건강 기록을 활용하여 고유한 애플리케이션을 지속적으로 개발할 수 있도록 할 것입니다.
VALD, une entreprise mondiale de technologie de la santé spécialisée dans la santé musculosquelettique (MSK), a obtenu un investissement important en fonds propres de croissance de la part de FTV Capital. Cet investissement permettra à VALD de s'étendre géographiquement, d'améliorer les capacités des produits et de consolider sa position en tant que pionnier mondial de la technologie dans le domaine de la santé MSK.
La suite complète de technologies MSK de VALD aide les professionnels de la santé à améliorer leurs capacités de diagnostic et à capturer des données en temps réel, favorisant ainsi de meilleurs résultats. L'entreprise a montré une croissance leader sur le marché, avec des revenus plus que triplés depuis 2021 et un personnel dans plus de 30 pays. VALD sert des clients mondiaux de premier plan, y compris 75% des franchises sportives majeures, 90% des universités Power 5 de la NCAA et de nombreux systèmes de santé et cliniques.
L'investissement permettra à VALD de développer son équipe mondiale, de lancer de nouvelles offres de produits et de continuer à utiliser l'IA pour créer des applications uniques à partir de son ensemble de données propriétaire comprenant des dizaines de millions de dossiers de santé MSK.
VALD, ein globales Unternehmen für Gesundheitstechnologie, das sich auf muskuloskelettale (MSK) Gesundheit spezialisiert hat, hat eine bedeutende Wachstumsinvestition von FTV Capital gesichert. Diese Investition ermöglicht es VALD, geografisch zu expandieren, Produktfähigkeiten zu verbessern und seine Position als globaler Technologieführer im Bereich MSK-Gesundheit zu festigen.
Das umfassende Angebot an MSK-Technologien von VALD unterstützt Gesundheitsfachkräfte dabei, die diagnostischen Fähigkeiten zu verbessern und Echtzeitdaten zu erfassen, was zu besseren Ergebnissen führt. Das Unternehmen hat ein marktführendes Wachstum gezeigt, mit mehr als dreifachem Umsatz seit 2021 und Mitarbeitern in über 30 Ländern. VALD bedient globale Top-Kunden, darunter 75% der großen Sportfranchisen, 90% der Power 5 NCAA Colleges und zahlreiche Gesundheitssysteme und Kliniken.
Die Investition wird es VALD ermöglichen, sein globales Team auszubauen, neue Produktangebote einzuführen und KI weiterhin zu nutzen, um einzigartige Anwendungen für seinen proprietären Datensatz von zig Millionen MSK-Gesundheitsregistern zu erstellen.
- Secured significant growth equity investment from FTV Capital
- Revenue more than tripled since 2021
- Staff presence in over 30 countries
- Serves 75% of major league sports franchises and 90% of Power 5 NCAA colleges
- Proprietary dataset of tens of millions of MSK health records
- None.
Insights
VALD's significant growth equity investment from FTV Capital marks a pivotal moment for the company and the musculoskeletal (MSK) health technology sector. The investment underscores the market's recognition of VALD's potential in a $12 billion annual spending market in the U.S. alone. With revenue more than tripling since 2021 and a rapidly expanding global presence, VALD is positioned for accelerated growth.
The company's impressive client roster, including 75
For investors, this development signals strong growth potential in the digital health sector, particularly in MSK health. The backing of FTV Capital, known for its sector expertise, adds credibility and potentially opens doors for strategic partnerships. However, investors should monitor how effectively VALD utilizes this capital for expansion and product development, as execution will be key to realizing the projected growth.
VALD's technology addresses a critical gap in musculoskeletal health management by digitizing and enhancing diagnostic capabilities. The company's approach of bringing advanced laboratory-grade tools to everyday clinical settings has significant implications for improving patient outcomes and reducing healthcare costs.
The rapid growth of VALD's dataset, roughly doubling each year, is particularly noteworthy. This vast collection of MSK health records provides a unique opportunity for developing AI-driven insights and predictive models, potentially revolutionizing treatment protocols and preventive care strategies in MSK health.
The investment from FTV Capital could accelerate VALD's R&D efforts, potentially leading to breakthroughs in MSK health management. For the healthcare industry, this could mean more efficient diagnosis, personalized treatment plans and better resource allocation. Investors should watch for upcoming product launches and clinical validations, as these will be key indicators of VALD's ability to translate its data advantage into tangible market leadership and revenue growth.
Investment will accelerate geographic expansion and enhance industry-leading product capabilities, cementing VALD’s position as a global technology pioneer in musculoskeletal health
MSK health is a historically underserviced and yet vast market. In the
“Over the past decade, we’ve been able to achieve rapid growth as a first mover in our industry, while the market still remains largely untapped,” said Laurie Malone, CEO and co-founder of VALD. “Our fully integrated suite of products, software solutions, and proprietary data empowers our customers to increase efficiencies within their workflows and ultimately improve their standard of care and patient outcomes. FTV brings an unmatched network of investors and advisors, as well as an intimate knowledge of the MSK industry, which are vital to capturing the massive opportunity in front of us and, more importantly, helping millions of patients, athletes, and tactical operators around the world suffering from MSK conditions.”
Since its founding in 2015, VALD has demonstrated market-leading growth with revenue more than tripling since 2021, staff in over 30 countries and a dataset of MSK records roughly doubling each year. VALD serves global blue-chip customers including over 75 percent of all major league sports franchises (e.g., NFL, NBA, MLB, NHL and MLS), over 90 percent of Power 5 NCAA colleges, 20 Premier League teams, the
“While demand for MSK health services is outpacing other conditions globally, the market is still in the early innings of its digital transformation,” said Alex Mason, partner at FTV Capital. “VALD’s end-to-end offering is viewed as mission critical by thousands of organizations who rely on its interactive, software-enabled platform to help measure, manage and improve human performance and mobility. We are excited to partner with Laurie and the VALD management team to help usher the company through its next phase of growth and reinforce its dominant position in the market.”
As part of this growth investment, Alex Mason and Justin Levine, vice president at FTV Capital, joined VALD’s board of directors.
About VALD
VALD is a world leader in musculoskeletal assessment and rehabilitation technologies. VALD technologies are used by thousands of the world’s most elite sports organizations, clinics, universities, hospitals and defense departments to measure human movement, performance and injury rehabilitation.
The VALD Suite centers around its software hub, which is populated by data from its ForceDecks Dual Force Plate System, NordBord Hamstring Testing System, ForceFrame Strength Testing System, DynaMo Handheld Strength and ROM, HumanTrak Movement Analysis System, SmartSpeed Timing Gate System, SmartJump Portable Jump Mat and TeleHab Exercise Prescription App.
About FTV Capital
FTV Capital is a sector-focused growth equity investment firm that has raised
View source version on businesswire.com: https://www.businesswire.com/news/home/20240925489242/en/
Media Contacts:
Prosek Partners on behalf of FTV Capital
pro-ftvcapital@prosek.com
646-818-9051
Source: FTV Capital
FAQ
What is the purpose of FTV Capital's investment in VALD?
How has VALD's revenue growth performed since 2021?
What percentage of major league sports franchises does VALD serve?
How will VALD use AI in its future developments?
